Alembic Pharmaceuticals Limited has informed the Exchange about press release dated 24-May-2022 titled Alembic Pharmaceuticals receives USFDA Final Approval for Pirfenidone Tablets, 267 mg and 801 mg.
Alembic Pharmaceuticals Limited has informed the Exchange about press release dated 24-May-2022 titled Alembic Pharmaceuticals receives USFDA Final Approval for Pirfenidone Tablets, 267 mg and 801 mg.